Previous 10 | Next 10 |
PRA Health Sciences ( PRAH -0.2% ) announced a new strategic relationship with Deep Lens, Inc., to accelerate patient access and recruitment for oncology clinical trials. More news on: PRA Health Sciences, Inc., Healthcare stocks news, Read more ...
The two companies bring together cloud-based mobile technologies to improve the identification, screening and matching of patients to precision-based clinical oncology trials RALEIGH, N.C. and COLUMBUS, Ohio, Sept. 18, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) and De...
RALEIGH, N.C., Sept. 15, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) today announced the appointment of Glen Stettin, M.D. to the Board of Directors of the Company, effective September 14, 2020. “We are delighted that Glen will be joining our Board of Directors.&...
This article is part of a series that provides an ongoing analysis of the changes made to Larry Robbins' 13F portfolio on a quarterly basis. It is based on Robbins' regulatory 13F Form filed on 08/14/2020. Please visit our Tracking Larry Robbins' Glenview Capital Management Portfolio artic...
RYE BROOK, N.Y. and RALEIGH, N.C. , Sept. 3, 2020 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and PRA Health Sciences (NASDAQ: PRAH) announced today a partnership to launch a first-of-its-kind global master clinical trial to develop new treatments for children with relapse...
Image source: The Motley Fool. PRA Health Sciences Inc (NASDAQ: PRAH) Q2 2020 Earnings Call Aug 7, 2020 , 9:00 a.m. ET Operator Continue reading
The following slide deck was published by PRA Health Sciences, Inc. in conjunction with their 2020 Q2 earnings Read more ...
PRA Health Sciences, Inc. (PRAH) Q2 2020 Results Conference Call August 07, 2020 09:00 AM ET Company Participants Chris Gaenzle - Chief Administrative Officer and General Counsel Colin Shannon - Chairman, CEO & President Mike Bonello - EVP, CFO & Corporate Secretary Co...
PRA Health Sciences (NASDAQ: PRAH ) : Q2 Non-GAAP EPS of $0.86 beats by $0.04 ; GAAP EPS of $0.22 misses by $0.17 . More news on: PRA Health Sciences, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Net new business of $701.6 million; Net book-to-bill of 1.35 excluding reimbursement revenue Net new business of $1,083.3 million; Net book-to-bill of 1.62 including reimbursement revenue $729.9 million of total revenue; representing a decrease of 4.4% at actual foreign exchange ra...
News, Short Squeeze, Breakout and More Instantly...
PRA Health Sciences Inc. Company Name:
PRAH Stock Symbol:
NASDAQ Market:
PRA Health Sciences Inc. Website:
DT Midstream Set to Join S&P MidCap 400 DT Midstream Set to Join S&P MidCap 400 PR Newswire NEW YORK , June 28, 2021 /PRNewswire/ -- DT Midstream Inc. (NYSE: DTM) will replace PRA Health Sciences Inc. (NASD: PRAH) in the S&P MidCap 400 effective p...
Through this strategic partnership, the network aims to reach more than 25,000 physicians and 40 million patients, accelerating trial recruitment and enrollment efforts and expanding patients’ access to clinical research Veradigm®, a leading provider of healthcar...
Strengthening Board of Directors with Expertise in Innovative Product Launches NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiat...